Evaluation of Preventive Role of Systemically Applied Erythropoietin after Tooth Extraction in a Bisphosphonate-Induced MRONJ Model

Basit Öğe Kaydı
dc.authoridSoluk Tekkesin, Merva/0000-0002-7178-3335
dc.authoridYalcin, Gul Merve/0000-0002-7438-5834
dc.contributor.authorDuygu, Gonca
dc.contributor.authorYalcin-Ulker, Guel Merve
dc.contributor.authorGunbatan, Murat
dc.contributor.authorSoluk-Tekkesin, Merva
dc.contributor.authorOzcakir-Tomruk, Ceyda
dc.date.accessioned2024-10-29T17:59:24Z
dc.date.available2024-10-29T17:59:24Z
dc.date.issued2023
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractBackground and Objectives: In this experimental study, the prophylactic effect of systemically administered erythropoietin (EPO) in medication-related osteonecrosis of the jaw (MRONJ) was evaluated. Materials and Methods: The osteonecrosis model was established using 36 Sprague Dawley rats. EPO was systemically applied before and/or after tooth extraction. Groups were formed based on the application time. All samples were evaluated histologically, histomorphometrically, and immunohistochemically. A statistically significant difference in new bone formation was observed between the groups (p < 0.001). Results: When new bone-formation rates were compared, no significant differences were observed between the control group and the EPO, ZA+PostEPO, and ZA+Pre-PostEPO groups (p = 1, 0.402, and 1, respectively); however, this rate was significantly lower in the ZA+PreEPO group (p = 0.021). No significant differences in new bone formation were observed between the ZA+PostEPO and ZA+PreEPO groups (p = 1); however, this rate was significantly higher in the ZA+Pre-PostEPO group (p = 0.009). The ZA+Pre-PostEPO group demonstrated significantly higher intensity level in VEGF protein expression than the other groups (p < 0.001). Conclusions: Administering EPO two weeks pre-extraction and continuing EPO treatment for three weeks post-extraction in ZA-treated rats optimized the inflammatory reaction, increased angiogenesis by inducing VEGF, and positively affected bone healing. Further studies are needed to determine the exact durations and doses.
dc.identifier.doi10.3390/medicina59061059
dc.identifier.issn1010-660X
dc.identifier.issn1648-9144
dc.identifier.issue6en_US
dc.identifier.pmid37374263
dc.identifier.scopus2-s2.0-85163735075
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.3390/medicina59061059
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14724
dc.identifier.volume59
dc.identifier.wosWOS:001014940400001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofMedicina-Lithuania
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectbisphosphonate
dc.subjecterythropoietin
dc.subjectmedication-related osteonecrosis of the jaw
dc.subjecttooth extraction
dc.titleEvaluation of Preventive Role of Systemically Applied Erythropoietin after Tooth Extraction in a Bisphosphonate-Induced MRONJ Model
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu